|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHL1 |
Gene summary for CHL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHL1 | Gene ID | 10752 |
| Gene name | cell adhesion molecule L1 like | |
| Gene Alias | CALL | |
| Cytomap | 3p26.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O00533 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10752 | CHL1 | LZE2T | Human | Esophagus | ESCC | 3.08e-04 | 7.85e-01 | 0.082 |
| 10752 | CHL1 | LZE24T | Human | Esophagus | ESCC | 6.08e-07 | 2.02e-01 | 0.0596 |
| 10752 | CHL1 | P4T-E | Human | Esophagus | ESCC | 5.55e-26 | 8.04e-01 | 0.1323 |
| 10752 | CHL1 | P8T-E | Human | Esophagus | ESCC | 2.40e-17 | 4.53e-01 | 0.0889 |
| 10752 | CHL1 | P9T-E | Human | Esophagus | ESCC | 1.72e-12 | 3.98e-01 | 0.1131 |
| 10752 | CHL1 | P10T-E | Human | Esophagus | ESCC | 3.16e-19 | 5.06e-01 | 0.116 |
| 10752 | CHL1 | P11T-E | Human | Esophagus | ESCC | 4.27e-06 | 5.38e-01 | 0.1426 |
| 10752 | CHL1 | P12T-E | Human | Esophagus | ESCC | 2.27e-09 | 2.56e-01 | 0.1122 |
| 10752 | CHL1 | P15T-E | Human | Esophagus | ESCC | 2.06e-02 | 1.98e-01 | 0.1149 |
| 10752 | CHL1 | P22T-E | Human | Esophagus | ESCC | 1.44e-02 | 1.36e-01 | 0.1236 |
| 10752 | CHL1 | P23T-E | Human | Esophagus | ESCC | 3.68e-04 | 2.47e-01 | 0.108 |
| 10752 | CHL1 | P26T-E | Human | Esophagus | ESCC | 1.09e-04 | 2.22e-01 | 0.1276 |
| 10752 | CHL1 | P27T-E | Human | Esophagus | ESCC | 1.19e-16 | 4.60e-01 | 0.1055 |
| 10752 | CHL1 | P28T-E | Human | Esophagus | ESCC | 2.02e-03 | 1.12e-01 | 0.1149 |
| 10752 | CHL1 | P30T-E | Human | Esophagus | ESCC | 7.10e-11 | 2.49e-01 | 0.137 |
| 10752 | CHL1 | P31T-E | Human | Esophagus | ESCC | 3.86e-04 | 1.13e-01 | 0.1251 |
| 10752 | CHL1 | P39T-E | Human | Esophagus | ESCC | 1.57e-09 | 2.95e-01 | 0.0894 |
| 10752 | CHL1 | P47T-E | Human | Esophagus | ESCC | 8.66e-03 | 1.81e-01 | 0.1067 |
| 10752 | CHL1 | P49T-E | Human | Esophagus | ESCC | 1.78e-15 | 1.10e+00 | 0.1768 |
| 10752 | CHL1 | P54T-E | Human | Esophagus | ESCC | 1.85e-25 | 8.92e-01 | 0.0975 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
| GO:005134810 | Cervix | CC | negative regulation of transferase activity | 60/2311 | 268/18723 | 2.77e-06 | 8.02e-05 | 60 |
| GO:004593610 | Cervix | CC | negative regulation of phosphate metabolic process | 88/2311 | 441/18723 | 2.92e-06 | 8.27e-05 | 88 |
| GO:001056310 | Cervix | CC | negative regulation of phosphorus metabolic process | 88/2311 | 442/18723 | 3.21e-06 | 8.77e-05 | 88 |
| GO:004232610 | Cervix | CC | negative regulation of phosphorylation | 77/2311 | 385/18723 | 1.09e-05 | 2.38e-04 | 77 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:000193310 | Cervix | CC | negative regulation of protein phosphorylation | 69/2311 | 342/18723 | 2.29e-05 | 4.01e-04 | 69 |
| GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
| GO:000646910 | Cervix | CC | negative regulation of protein kinase activity | 47/2311 | 212/18723 | 4.13e-05 | 6.36e-04 | 47 |
| GO:00336739 | Cervix | CC | negative regulation of kinase activity | 50/2311 | 237/18723 | 9.22e-05 | 1.21e-03 | 50 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00162367 | Cervix | CC | macroautophagy | 58/2311 | 291/18723 | 1.40e-04 | 1.70e-03 | 58 |
| GO:00105067 | Cervix | CC | regulation of autophagy | 61/2311 | 317/18723 | 2.61e-04 | 2.87e-03 | 61 |
| GO:00307057 | Cervix | CC | cytoskeleton-dependent intracellular transport | 40/2311 | 195/18723 | 7.92e-04 | 6.99e-03 | 40 |
| GO:00426924 | Cervix | CC | muscle cell differentiation | 69/2311 | 384/18723 | 8.12e-04 | 7.09e-03 | 69 |
| GO:00434099 | Cervix | CC | negative regulation of MAPK cascade | 37/2311 | 180/18723 | 1.17e-03 | 9.50e-03 | 37 |
| GO:00516541 | Cervix | CC | establishment of mitochondrion localization | 10/2311 | 29/18723 | 1.74e-03 | 1.31e-02 | 10 |
| GO:00094109 | Cervix | CC | response to xenobiotic stimulus | 78/2311 | 462/18723 | 2.39e-03 | 1.70e-02 | 78 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHL1 | SNV | Missense_Mutation | c.1279C>T | p.Leu427Phe | p.L427F | O00533 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| CHL1 | SNV | Missense_Mutation | rs541454458 | c.1879G>A | p.Val627Ile | p.V627I | O00533 | protein_coding | deleterious(0.03) | possibly_damaging(0.684) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CHL1 | SNV | Missense_Mutation | rs141644867 | c.1456N>T | p.Arg486Trp | p.R486W | O00533 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CHL1 | SNV | Missense_Mutation | novel | c.820N>A | p.Leu274Met | p.L274M | O00533 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CHL1 | insertion | Nonsense_Mutation | novel | c.2882_2883insAAAGGTTCAGAATGAGAAATAGCCAACT | p.Asn961LysfsTer8 | p.N961Kfs*8 | O00533 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CHL1 | deletion | Frame_Shift_Del | novel | c.3583delN | p.Gly1195AspfsTer58 | p.G1195Dfs*58 | O00533 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CHL1 | deletion | Frame_Shift_Del | novel | c.1086delN | p.Ser362ArgfsTer79 | p.S362Rfs*79 | O00533 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| CHL1 | SNV | Missense_Mutation | rs185238679 | c.1457G>A | p.Arg486Gln | p.R486Q | O00533 | protein_coding | deleterious(0.03) | probably_damaging(0.944) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHL1 | SNV | Missense_Mutation | c.2629N>T | p.His877Tyr | p.H877Y | O00533 | protein_coding | tolerated(1) | benign(0.283) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| CHL1 | SNV | Missense_Mutation | novel | c.2606N>T | p.Lys869Ile | p.K869I | O00533 | protein_coding | deleterious(0.03) | possibly_damaging(0.713) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |